文献速递免疫规划传染病防控与疫情报告

A组链球菌咽炎受控人类感染研究(CHIVAS)方案

Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study.
PubMed 文献 · Vaccine · 2019-05-14

A组链球菌(GAS)疫苗开发受科学、监管和商业障碍制约,人类感染研究可降低早期不确定性。本文回顾少量历史GAS人类感染研究,并报告一项在健康成人中进行的剂量递增住院研究方案,主要目标是建立攻击率至少60%的GAS咽炎人类感染模型,作为疫苗评价和发病机制研究的安全可靠平台。

要点

  • GAS人类感染研究可加速疫苗开发并降低早期不确定性。
  • CHIVAS研究采用适应性剂量递增设计,以emm75 GAS咽部接种健康成人。
  • 主要目标为建立攻击率至少60%的GAS咽炎人类感染模型。

核心结论

  • 研究方案旨在建立攻击率至少60%的GAS咽炎人类感染模型,作为疫苗评价和发病机制研究的安全可靠平台。

研究设计与样本

  • 本研究为剂量递增住院研究,采用适应性剂量递增设计,在健康成人志愿者中通过咽部拭子直接接种符合良好生产规范原则制备的emm75 GAS菌株。
  • 参与者为仔细筛选的、严重复杂GAS疾病风险低的健康成人志愿者,住院密切监测最长6天,治疗后门诊随访6个月。
  • 研究已获伦理批准并在ClinicalTrials.gov注册(NCT03361163)。

主要发现

  • 原文回顾了少量历史GAS人类感染研究,但未报告具体历史研究结果数据。

关键数值与推荐

  • 主要结局为急性症状性咽炎,由临床和微生物学标准定义。
  • 所有参与者将接受抗生素治疗并作为门诊患者随访6个月。
  • 密集采样计划将促进实验性咽炎期间宿主和病原体动力学的广泛研究。

临床怎么用

  • 该人类感染模型若建立成功,可用于GAS疫苗的早期评价和发病机制研究。

局限性

  • 原文未报告研究的实际结果数据,仅报告了研究方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Group A Streptococcus (GAS) is a highly-adapted and human-restricted pathogen responsible for a high global burden of disease across a diverse clinical spectrum. Vaccine development has been impeded by scientific, regulatory, and commercial obstacles. Human infection studies (HIS) are increasingly contributing to drug, diagnostics, and vaccine development, reducing uncertainty at early stages, especially for pathogens with animal models that incompletely reproduce key elements of human disease. We review the small number of historical GAS HIS and present the study protocol for a dose-ranging inpatient study in healthy adults. The primary objective of the study is to establish a new GAS pharyngitis HIS with an attack rate of at least 60% as a safe and reliable platform for vaccine evaluation and pathogenesis research. According to an adaptive dose-ranging study design, emm75 GAS doses manufactured in keeping with principles of Good Manufacturing Practice will be directly applied by swab to the pharynx of carefully screened healthy adult volunteers at low risk of severe complicated GAS disease. Participants will remain as closely monitored inpatients for up to six days, observed for development of the primary outcome of acute symptomatic pharyngitis, as defined by clinical and microbiological criteria. All participants will be treated with antibiotics and followed as outpatients for six months. An intensive sampling schedule will facilitate extensive studies of host and organism dynamics during experimental pharyngitis. Ethics approval has been obtained and the study has been registered at ClinicalTrials.gov (NCT03361163).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Osowicki J, Azzopardi KI, Baker C, et al. Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. Vaccine. 2019. PMID: 31101422. doi:10.1016/j.vaccine.2019.03.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。